Composite probiotic preparation containing various bifidobacteria and application thereof

Abstract

The invention discloses a compound probiotic preparation containing various bifidobacteria and an application of the compound probiotic preparation. The compound probiotic preparation is prepared from bifidobacterium bifidum, bifidobacterium longum subsp. Longum subsp. Longum, bifidobacterium breve, bifidobacterium longum subsp. Longum subsp. Infantis and bifidobacterium adolescentis, and the compound probiotic preparation containing the various bifidobacteria comprises the following components: bifidobacterium bifidum, bifidobacterium longum subsp. Longum subsp. Longum subsp. Longum subsp. Longum subsp. Longum subsp. Longum subsp. Longum subsp. Longum subsp. Longum, bifidobacterium adolescentis and bifidobacterium adolescentis. The compound probiotic preparation disclosed by the invention can be used for improving the microecology of intestinal tracts, exerting the synergistic effect of multiple strains, improving the health of the intestinal tracts and related metabolism and immunity problems more comprehensively, and further exerting better health-care and prevention effects.

Description

Technical Field

[0001] This invention relates to the field of microbial technology, specifically to a compound probiotic preparation containing multiple Bifidobacteria and its application. Background Technology

[0002] Gut microbiota imbalance is associated with various diseases. Bifidobacteria, as beneficial bacteria inherent in the human gut, decrease with age. Current probiotic products use single strains and cannot comprehensively mimic a healthy gut microbiota. This invention addresses the problem of insufficient functional coverage of strains in existing technologies by combining multiple Bifidobacteria strains for synergistic effects. Traditional single-strain probiotic products may have limitations in efficacy; therefore, it is necessary to develop compound probiotic formulations with synergistic effects of multiple strains to achieve better health maintenance and preventative effects. Summary of the Invention

[0003] In view of this, the purpose of this invention is to provide a compound probiotic preparation containing multiple Bifidobacteria and its application, which solves the problems of existing probiotic preparations in restoring and maintaining the balance of human intestinal microecology, such as single strain, insufficient functional coverage, and weak synergistic effect.

[0004] To achieve the above objectives, the present invention provides the following technical solution: A compound probiotic preparation containing multiple Bifidobacteria, including Bifidobacterium bifidum, Bifidobacterium longum subsp. longum, Bifidobacterium breve, Bifidobacterium longum subsp. infantis, and Bifidobacterium adolescentis.

[0005] The *Bifidobacterium bifidum* strain is BB-G90, *Bifidobacterium longum* subsp. longum is BL-G301, *Bifidobacterium breve* is BB-G95, *Bifidobacterium longum* subsp. infantis is BI-G201, and *Bifidobacterium adolescentis* is BQ-G66.

[0006] Preferably, the viable count ratio of the following strains is 9~11:4~6:180~190:0.5~1.5:1~3.

[0007] Preferably, the present invention also includes prebiotics, wherein the prebiotics include at least one of resistant dextrin, erythritol, sweet orange juice powder, zinc-enriched yeast powder, selenium-enriched malt powder, oat β-glucan, galactooligosaccharide, and galactomannan.

[0008] Preferably, the prebiotics of this invention, by weight, comprise 250-350 parts resistant dextrin, 350-450 parts erythritol, 130-150 parts sweet orange juice powder, 9-11 parts zinc-enriched yeast powder, 1.5-2.5 parts selenium-enriched malt powder, 18-22 parts oat β-glucan, 350-430 parts galactooligosaccharides, and 180-220 parts galactomannan.

[0009] Preferably, the present invention also includes an excipient, wherein the excipient is maltodextrin.

[0010] Preferably, the dosage form of the compound probiotic preparation is an oral liquid, granule, powder, lyophilized powder, aqueous solution, emulsion, tablet, soft candy, or capsule.

[0011] Application of a compound probiotic preparation containing multiple Bifidobacteria in the preparation of foods, health products, special medical purpose formula foods, and drugs for improving intestinal microecology.

[0012] Preferably, the compound probiotic preparation is used in the preparation of foods, health products, special medical purpose formula foods, or drugs for regulating celiac disease or relieving constipation.

[0013] A method for preparing a compound probiotic preparation containing multiple Bifidobacteria, characterized in that the compound probiotic preparation is prepared by mixing the various components.

[0014] The beneficial effects of this invention are as follows: by supplementing with specific types of Bifidobacteria, it can improve the intestinal microecology, thereby improving overall health and overcoming the limitations in efficacy of traditional single-strain probiotic products. Through the implementation of this invention, by combining specific Bifidobacterium strains with prebiotics and nutrients, the synergistic effect of multiple strains can be achieved, which can more comprehensively improve intestinal health and related metabolic and immune problems, thereby playing a better role in health care and prevention. Attached Figure Description

[0015] To make the objectives, technical solutions, and beneficial effects of this invention clearer, the following figures are provided for illustration: Figure 1 This diagram shows the expression of tumor necrosis factor (TNF-α) and nuclear factor kappa-B p65 subunit (NF-κB p65) in Caco-2 cell culture. Figure 2 Neutral red uptake in Caco-2 cell cultures after exposure to gluten-digesting peptides produced from probiotic preparation cultures; Figure 3 A graph illustrating the intestinal peristalsis inhibition effect of probiotic preparations in a study on the anti-constipation effect; Figure 4 The graph shows the effect of probiotic preparations on the number of fecal particles, defecation time, and total fecal weight in experimental animals with constipation. Detailed Implementation

[0016] The present invention will be further described below with reference to the accompanying drawings and specific embodiments, so that those skilled in the art can better understand and implement the present invention. However, the embodiments described are not intended to limit the present invention.

[0017] Example 1: Compound Probiotic Preparation The viable count ratio of Bifidobacterium bifidum BB-G90 strain, Bifidobacterium longum subsp. longum BL-G301 strain, Bifidobacterium breve BB-G95 strain, Bifidobacterium longum subsp. infantum BI-G201 strain, and Bifidobacterium adolescentis BQ-G66 strain was 10:5:184:1:2.

[0018] 300 parts resistant dextrin, 400 parts erythritol, 140 parts sweet orange juice powder, 10 parts zinc-enriched yeast powder, 2 parts selenium-enriched malt powder, 20 parts oat β-glucan, 380 parts galactooligosaccharide, and 200 parts galactomannan.

[0019] 468.67 portions of maltodextrin.

[0020] Example 2: Study on the regulation of celiac disease by probiotic preparations Celiac disease (CD) is a chronic illness caused by an autoimmune response triggered by gluten consumption, characterized by an inflammatory process. While grains such as rye and barley also contain gluten, wheat is the primary dietary source. Gluten components, including prolamins and glutenin, are commonly associated with the development of celiac disease. They are characterized by their high proline and glutamine residue content. Abnormalities in the gut microbiota composition of patients with celiac disease are closely related to disease severity, with dysbiosis characterized by a significant reduction in Gram-positive bacteria, followed by a significant increase in some potentially harmful Gram-negative bacteria.

[0021] This study evaluated the effects of a probiotic formulation on the digestion of intact gluten proteins (prolamins and glutenin) and the resulting peptides on the immunomodulatory response. These peptides significantly reduced cytotoxic responses and pro-inflammatory marker levels compared to gluten fragments generated during uninoculated gastrointestinal digestion. Cell cultures were exposed (15 and 48 hours) to a probiotic formulation containing digested gluten peptides (0.25 mg / mL) formed from gluten proteins (Prot.). Non-biological gastrointestinal digests of gluten proteins were used as negative (Neg.) and positive (Pos.) controls. The results highlight the potential of probiotic formulations as a treatment for celiac disease (CD). Figure 1 Neutral red uptake in Caco-2 cell cultures after exposure to gluten-digesting peptides (0.25 mg / mL) derived from Bifidobacterium cultures (15 and 48 hours) is shown in the table below. Figure 2 .

[0022] In this study, we found that probiotic preparations can aid in the proteolysis of intact gluten proteins, prolamins, and glutenin, forming different peptide patterns. Compared to traditional immunogenic gluten peptides, these peptides exhibited significantly reduced cytotoxicity and pro-inflammatory responses in intestinal epithelial cells. This research provides a foundation for a better understanding of the role of probiotic preparations in gluten digestion and opens new avenues for circumventing the harmful effects of gluten intake in patients with celiac disease.

[0023] Example 3: Research on the anti-constipation effects of probiotic preparations Probiotics produce lactic acid through metabolism in the intestines, which effectively inhibits the growth and reproduction of harmful bacteria. Probiotics can also increase intestinal peristalsis and increase the water content of feces, which is very important for maintaining the normal physiological function of the gastrointestinal tract.

[0024] This experiment used oral gavage to administer the drug. Different groups were given a charcoal suspension via gavage, and the length of charcoal propulsion and the total length of the small intestine were measured to determine the effect of the sample on small intestinal propulsion. The results are shown in the figure. After treating mice with gastric lavage, the time of the first black feces and the number of defecations within 6 hours were recorded.

[0025] The inhibitory effect of probiotic preparations on intestinal motility induced by diphenoxylate is shown in [reference needed]. Figure 3 The difference between the normal control group and the diphenoxylate control group was statistically significant, indicating that the constipation model had been established. After 10 days of oral administration of different doses of the samples, they were found to counteract the inhibitory effect of diphenoxylate on intestinal peristalsis. The high-dose group was statistically significantly different from the diphenoxylate control group (P<0.05).

[0026] The effects of probiotic preparations on fecal particle number, defecation time, and total fecal weight in constipated experimental animals are shown in the figure. Figure 4 The results showed that the probiotic preparation could significantly counteract the intestinal inhibition caused by diphenoxylate, restore the animals' intestinal propulsion ability, increase the frequency and total amount of defecation, shorten the time of the first defecation, and have a laxative effect. The high-dose group had the most significant effect.

Claims

1. A compound probiotic preparation containing multiple Bifidobacteria, characterized in that, This includes *Bifidobacterium bifidum*, *Bifidobacterium longum subsp. longum*, *Bifidobacterium breve*, *Bifidobacterium longum subsp. infantis*, and *Bifidobacterium adolescentis*.

2. The compound probiotic preparation containing multiple Bifidobacteria according to claim 1, characterized in that, The *Bifidobacterium bifidum* strain is BB-G90, *Bifidobacterium longum subsp. longum* strain is BL-G301, *Bifidobacterium breve* strain is BB-G95, *Bifidobacterium longum subsp. infantis* strain is BI-G201, and *Bifidobacterium adolescentis* strain is BQ-G66.

3. The compound probiotic preparation containing multiple Bifidobacteria according to claim 1, characterized in that, The viable count ratio of the following strains is 9~11:4~6:180~190:0.5~1.5:1~3.

4. A compound probiotic preparation containing multiple Bifidobacteria according to claim 1, characterized in that, It also includes prebiotics, which include at least one of resistant dextrin, erythritol, sweet orange juice powder, zinc-enriched yeast powder, selenium-enriched malt powder, oat beta-glucan, galactooligosaccharides, and galactomannan.

5. A compound probiotic preparation containing multiple Bifidobacteria according to claim 4, characterized in that, The prebiotics, by weight, include 250-350 parts resistant dextrin, 350-450 parts erythritol, 130-150 parts sweet orange juice powder, 9-11 parts zinc-enriched yeast powder, 1.5-2.5 parts selenium-enriched malt powder, 18-22 parts oat β-glucan, 350-430 parts galactooligosaccharides, and 180-220 parts galactomannan.

6. A compound probiotic preparation containing multiple Bifidobacteria according to claim 4, characterized in that, It also includes excipients, namely maltodextrin.

7. A compound probiotic preparation containing multiple Bifidobacteria according to any one of claims 1 to 6, characterized in that, The dosage form of the compound probiotic preparation is oral liquid, granules, powder, lyophilized powder, aqueous solution, emulsion, tablet, soft candy or capsule.

8. The use of a compound probiotic preparation containing multiple Bifidobacteria as described in any one of claims 1-7 in the preparation of foods, health products, special medical purpose formula foods, and drugs for improving intestinal microecology.

9. The use of a compound probiotic preparation containing multiple Bifidobacteria as described in any one of claims 1-7 in the preparation of foods, health products, special medical purpose formula foods or drugs for regulating celiac disease or relieving constipation.

10. A method for preparing a compound probiotic preparation containing multiple Bifidobacteria as described in any one of claims 1-7, characterized in that, The compound probiotic preparation is prepared by mixing the various components.

Images